Ocaliva
Payments companies reported to CMS as associated with Ocaliva. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ocaliva, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ocaliva
These are the largest totals companies reported as associated with Ocaliva. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Haytham Elgammal | Miami, FL | Internal Medicine | $1,732,119.06 |
| Keith Gottesdiener | Rahway, NJ | Infectious Disease | $364,872.09 |
| Robert Gish | Folsom, CA | Hepatology | $211,273.07 |
| Sonal Kumar | New York, NY | Gastroenterology (Internal Medicine) | $139,704.14 |
| Robert Reindollar | Salisbury, NC | Gastroenterology (Internal Medicine) | $122,170.83 |
| Nezam Afdhal | Boston, MA | Hepatology | $118,266.00 |
| Christopher Wohlberg | Allentown, PA | Neurology (Psychiatry & Neurology) | $102,675.00 |
| Hany Elbeshbeshy | Saint Louis, MO | Hepatology | $101,222.80 |
| Lance Stein | Atlanta, GA | Transplant Hepatology | $96,847.91 |
| Robert Brown | New York, NY | Hepatology | $92,909.82 |
Prescribed Ocaliva?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.